A- A A+

Barriers to accessing opioid agonist therapy in pregnancy. 

Bedrick BS, O'Donnell C, Marx CM, Friedman H, Carter EB, Stout MJ, Kelly JC. 

Am J Obstet Gynecol MFM. 2020 Nov;2(4):100225. doi: 10.1016/j.ajogmf.2020.100225. Epub 2020 Sep 15. PMID: 33345932.


Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis. 

Link HM, Jones H, Miller L, Kaltenbach K, Seligman N. 

Am J Obstet Gynecol MFM. 2020 Aug;2(3):100179. doi: 10.1016/j.ajogmf.2020.100179. Epub 2020 Jul 3. PMID: 33345863.


Medication-assisted treatment vs. detoxification for women who misuse opioids in pregnancy: Associations with dropout, relapse, neonatal opioid withdrawal syndrome (NOWS), and childhood sexual abuse. 

Macfie J, Towers CV, Fortner KB, Stuart GL, Zvara BJ, Kurdziel-Adams G, Kors SB, Noose SK, Gorrondona AM, Cohen CT. 

Addict Behav Rep. 2020 Nov 12;12:100315. doi: 10.1016/j.abrep.2020.100315. PMID: 33364323; PMCID: PMC7752716.


Use of Injectable Opioid Agonist Therapy in a In-Patient Setting for a Pregnant Patient With Opioid Use Disorder: A Case Report. 

Griffiths S, Campbell DM, Caudarella A, Guimond T, Lamba W, Lurie E, Nader M, Sgro M, Turner S. 

J Addict Med. 2020 Nov 23. doi: 10.1097/ADM.0000000000000776. Epub ahead of print. PMID: 33234803.



Maintenance agonist treatments for opiate-dependent pregnant women. 

Minozzi S, Amato L, Jahanfar S, Bellisario C, Ferri M, Davoli M. 

Cochrane Database Syst Rev. 2020 Nov 9;11:CD006318. doi: 10.1002/14651858.CD006318.pub4. PMID: 33165953.


Pregnancy and Substance Use – A Harm Reduction Toolkit

NATIONAL HARM REDUCTION COALITION in Collaboration with Academy of Perinatal Harm Reduction 


Changing Outdated Methadone Regulations That Harm Pregnant Patients 

McCarthy JJ, Jones HE, Terplan M, Rudolf VP, von Klimo MC. 

[published online ahead of print, 2020 Aug 18]. J Addict Med. 2020;10.1097/ADM.0000000000000720. doi:10.1097/ADM.0000000000000720



Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use Disorder. 

Patrick SW, Richards MR, Dupont WD, et al. 

JAMA Netw Open. 2020;3(8):e2013456. Published 2020 Aug 3. doi:10.1001/jamanetworkopen.2020.13456


Associations of Maternal Prenatal Drug Abuse With Measures of Newborn Brain Structure, Tissue Organization, and Metabolite Concentrations 

Peterson BS, Rosen T, Dingman S, et al. 

[published online ahead of print, 2020 Jun 15]. JAMA Pediatr. 2020;e201622. 


Opioid use disorder in pregnancy

Anshula Ambasta and Mary Malebranche

CMAJ September 23, 2019 191 (38) E1057; DOI: doi.org/10.1503/cmaj.190391 


Medications for opioid use disorder among pregnant women referred by criminal justice agencies before and after Medicaid expansion: A retrospective study of admissions to treatment centers in the United States.

Winkelman TNA, Ford BR, Shlafer RJ, McWilliams A, Admon LK, Patrick SW (2020) 

PLoS Med 17(5): e1003119. doi.org/10.1371/journal.pmed.1003119


DAH. "DU LIEBES KIND" - Drogengebrauch und Schwangerschaft

Die DAH hat ein neues Medium mit Dr Siedentopf und Frau Nagel von der Charite veröffentlicht. "DU LIEBES KIND", Es geht um Drogengebrauch und Schwangerschaft und gibt Antworten auf viele Fragen rund um das Thema Schwangerschaft gibt, beispielsweise: Darf eine Drogenabhängige überhaupt Kinder bekommen? Können Drogen dem Kind schaden? Drogen und Mutterschaft? Muss die Lebensführung geändert werden? - Mit Adressen von Beratungsstellen.

Frauen die Drogen gebrauchen werden mit Informationen versorgt, die sie durch die Zeit vor, während und nach ihrer Schwangerschaft begleiten. Dazu gibt es Checklisten und das Thema Substitution spielt eine Rolle. (DAH – Deutsche AIDS-Hilfe, Broschüre, vollständig überarbeitete Auflage im neuen Design, 56 Seiten, 2020)


Breastfeeding Intention Compared With Breastfeeding Postpartum Among Women Receiving Medication-Assisted Treatment.

Yonke N, Maston R, Weitzen S, Leeman L.

J Hum Lact. 2019 Feb;35(1):71-79. doi: 10.1177/0890334418769637. 



Alcohol and Psychoactive Drugs in Pregnancy.

Hetea A, Cosconel C, Stanescu AAM, Simionescu AA.

Maedica (Buchar). 2019 Dec;14(4):397-401. doi: 10.26574/maedica.2019.14.4.397.


Potential effects of using non-combustible tobacco and nicotine products during pregnancy: a systematic review.

Glover, M., Phillips, C.V. 

Harm Reduct J 17, 16 (2020). doi.org/10.1186/s12954-020-00359-2


Treatment of Opioid Use Disorder in Pregnant Women via Telemedicine: A Nonrandomized Controlled Trial.

Guille C, Simpson AN, Douglas E, Boyars L, Cristaldi K, McElligott J, Johnson D, Brady K.

JAMA Netw Open. 2020 Jan 3;3(1):e1920177. doi: 10.1001/jamanetworkopen.2019.20177.


Maternal prescribed opioid analgesic use during pregnancy and associations with adverse birth outcomes: A population-based study.

Sujan AC, Quinn PD, Rickert ME, Wiggs KK, Lichtenstein P, Larsson H, et al. (2019) 

PLoS Med 16(12): e1002980. doi.org/10.1371/journal.pmed.1002980


Opioid use disorder in pregnancy.

Harter K.

Ment Health Clin. 2019 Nov 27;9(6):359-372. doi: 10.9740/mhc.2019.11.359.


Antepartum Drug Dependence and Pregnancy- or Birth-related Complications: A Cross-sectional Study of 19 Million Inpatients.

Ahmad N, Robert CA, Jampa A, Ashraf S, Patel RS.

Cureus. 2019 Nov 10;11(11):e6117. doi: 10.7759/cureus.6117.


Naltrexone use in pregnancy: a time for change.

Caritis SN, Venkataramanan R.

Am J Obstet Gynecol. 2020 Jan;222(1):1-2. doi: 10.1016/j.ajog.2019.08.041. 


Life-long impairment of glucose homeostasis upon prenatal exposure to psychostimulants.

Korchynska S, Krassnitzer M, Malenczyk K, Prasad RB, Tretiakov EO, Rehman S, Cinquina V, Gernedl V, Farlik M, Petersen J, Hannes S, Schachenhofer J, Reisinger SN, Zambon A, Asplund O, Artner I, Keimpema E, Lubec G, Mulder J, Bock C, Pollak DD, Romanov RA, Pifl C, Groop L, Hökfelt TG, Harkany T.

EMBO J. 2019 Nov 21:e100882. doi: 10.15252/embj.2018100882.


Preventing the Use of Marijuana: Focus on Women and Pregnancy

This guide supports health care providers, systems, and communities seeking to prevent marijuana use among pregnant women. It describes relevant research findings, examines emerging and best practices, identifies knowledge gaps and implementation challenges, and offers useful resources. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, Dezember 2019)


Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study.

Mullins N, Galvin SL, Ramage M, Gannon M, Lorenz K, Sager B, Coulson CC.

J Addict Med. 2019 Sep 17. doi: 10.1097/ADM.0000000000000562.



The Impact of Hepatitis C Virus Infection on Buprenorphine Dose in Pregnancy.

McDowell ML, Tonismae TR, Slaven JE, Abernathy MP, Shanks AL, Benjamin TD, Quinney SK.

Am J Perinatol. 2019 Oct 26. doi: 10.1055/s-0039-1698838.



U.S. Surgeon General’s Advisory: Marijuana Use and the Developing Brain

I, Surgeon General VADM Jerome Adams, am emphasizing the importance of protecting our Nation from the health risks of marijuana use in adolescence and during pregnancy. Recent increases in access to marijuana and in its potency, along with misperceptions of safety of marijuana endanger our most precious resource, our nation’s youth. (Office of the Surgeon General, USA, November 2019)


Educational achievement at age 9.5 years of children born to mothers maintained on methadone during pregnancy.

Lee SJ, Woodward LJ, Henderson JMT (2019) 

PLoS ONE 14(10): e0223685. doi.org/10.1371/journal.pone.0223685


Use of Kratom, an Opioid-like Traditional Herb, in Pregnancy.

Smid MC, Charles JE, Gordon AJ, Wright TE.

Obstet Gynecol. 2018 Oct;132(4):926-928. doi: 10.1097/AOG.0000000000002871.



State Strategies to Address Opioid Use Disorder Among Pregnant and Postpartum Women and Infants Prenatally Exposed to Substances, Including Infants with Neonatal Abstinence Syndrome.

Kroelinger CD, Rice ME, Cox S, et al. 

MMWR Morb Mortal Wkly Rep 2019;68:777–783. DOI: doi.org/10.15585/mmwr.mm6836a1


Prenatal Exposure to Methamphetamine: Up-Regulation of Brain Receptor Genes.

Zoubková H, Tomášková A, Nohejlová K, Černá M, Šlamberová R.

Front Neurosci. 2019 Aug 1;13:771. doi: 10.3389/fnins.2019.00771.


Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines [Internet].

Edge R, Butcher R.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May 9. PMID: 31479216